Patents by Inventor Leonid A. Rozov
Leonid A. Rozov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9102604Abstract: A method for cleaning a distilling column includes providing a distilling column including a packing containing nickel and adding hydrochloric acid to the distilling column to wash at least a portion of the packing, thereby cleaning the distilling column.Type: GrantFiled: February 15, 2010Date of Patent: August 11, 2015Assignees: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE SAInventors: Leonid A. Rozov, Linas Kudzma, Hong-Chang Lee, Ronald Bell
-
Patent number: 8729313Abstract: The present invention provides a method for forming sevoflurane comprising (i) combining chlorosevo ether, a nucleophilic fluoride reagent, and a solvent comprising sevoflurane to form an initial reaction mixture and (ii) reacting the initial reaction mixture to form additional sevoflurane relative to the amount of sevoflurane present in the initial reaction mixture. The present disclosure is also directed to a method for forming sevoflurane, comprising: initiating a reaction between chlorosevo ether and a nucleophilic fluoride reagent in an initial reaction mixture further comprising a solvent comprising sevoflurane, thereby forming additional sevoflurane relative to the amount of sevoflurane present in the initial reaction mixture.Type: GrantFiled: August 15, 2011Date of Patent: May 20, 2014Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Linas Kudzma, Ronald Bell, Yongxian Zeng, Leonid A. Rozov
-
Publication number: 20130046117Abstract: The present invention provides a method for forming sevoflurane comprising (i) combining chlorosevo ether, a nucleophilic fluoride reagent, and a solvent comprising sevoflurane to form an initial reaction mixture and (ii) reacting the initial reaction mixture to form additional sevoflurane relative to the amount of sevoflurane present in the initial reaction mixture. The present disclosure is also directed to a method for forming sevoflurane, comprising: initiating a reaction between chlorosevo ether and a nucleophilic fluoride reagent in an initial reaction mixture further comprising a solvent comprising sevoflurane, thereby forming additional sevoflurane relative to the amount of sevoflurane present in the initial reaction mixture.Type: ApplicationFiled: August 15, 2011Publication date: February 21, 2013Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.Inventors: Linas Kudzma, Ronald Bell, Yongxian Zeng, Leonid A. Rozov
-
Patent number: 7375254Abstract: Provided is a process of obtaining 1,1,1,3,3,3-hexafluoro-2-propanol (“HFIP”) from a composition comprising an HFIP hydrolyzable precursor. The HFIP hydrolyzable precursor is a compound, other than sevoflurane itself, that has an intact 1,1,1,3,3,3-hexafluoroisopropoxy moiety[(CF3)2CHO—], and contains one or more moieties susceptible to acidic hydrolysis, such that HFIP is released upon such treatment. The process is useful, among other things, for recovering HFIP from waste streams associated with the synthesis of the inhalation anesthetic, fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether (“sevoflurane”). The process includes heating the composition with a strong protic acid to a temperature effective to hydrolyze at least some of the HFIP hydrolyzable precursor to HFIP, and then isolating the HFIP from the heated composition.Type: GrantFiled: May 24, 2005Date of Patent: May 20, 2008Assignee: Baxter International Inc.Inventors: Leonid A. Rozov, Ralph A. Lessor
-
Patent number: 6987204Abstract: Provided is a process of obtaining 1,1,1,3,3,3-hexafluoro-2-propanol (“HFIP”) from a composition comprising an HFIP hydrolyzable precursor. The HFIP hydrolyzable precursor is a compound, other than sevoflurane itself, that has an intact 1,1,1,3,3,3-hexafluoroisopropoxy moiety[(CF3)2CHO—], and contains one or more moieties susceptible to acidic hydrolysis, such that HFIP is released upon such treatment. The process is useful, among other things, for recovering HFIP from waste streams associated with the synthesis of the inhalation anesthetic, fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether (“sevoflurane”). The process includes heating the composition with a strong protic acid to a temperature effective to hydrolyze at least some of the HFIP hydrolyzable precursor to HFIP, and then isolating the HFIP from the heated composition.Type: GrantFiled: January 12, 2004Date of Patent: January 17, 2006Assignee: Baxter International Inc.Inventors: Leonid A. Rozov, Ralph A. Lessor
-
Publication number: 20050222468Abstract: Provided is a process of obtaining 1,1,1,3,3,3-hexafluoro-2-propanol (“HFIP”) from a composition comprising an HFIP hydrolyzable precursor. The HFIP hydrolyzable precursor is a compound, other than sevoflurane itself, that has an intact 1,1,1,3,3,3-hexafluoroisopropoxy moiety[(CF3)2CH—], and contains one or more moieties susceptible to acidic hydrolysis, such that HFIP is released upon such treatment. The process is useful, among other things, for recovering HFIP from waste streams associated with the synthesis of the inhalation anesthetic, fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether (“sevoflurane”). The process includes heating the composition with a strong protic acid to a temperature effective to hydrolyze at least some of the HFIP hydrolyzable precursor to HFIP, and then isolating the HFIP from the heated composition.Type: ApplicationFiled: May 24, 2005Publication date: October 6, 2005Inventors: Leonid Rozov, Ralph Lessor
-
Patent number: 6800786Abstract: Provided is a method for the preparation of desflurane wherein isoflurane is reacted with 0.7-1.2 mol. % of antimony pentachloride and 1.3-2.2 molar equivalents of hydrogen fluoride. Typically, the method is conducted by addition of hydrogen fluoride to a mixture of isoflurane and antimony pentachloride. After the addition of hydrogen fluoride is completed, the reaction is preferably maintained at temperatures of about 9-18° C. for about 6 to 7 hours, before being quenched.Type: GrantFiled: August 21, 2003Date of Patent: October 5, 2004Assignee: Baxter International, Inc.Inventors: Leonid A. Rozov, Ralph A. Lessor
-
Publication number: 20040147779Abstract: Provided is a process of obtaining 1,1,1,3,3,3-hexafluoro-2-propanol (“HFIP”) from a composition comprising an HFIP hydrolyzable precursor. The HFIP hydrolyzable precursor is a compound, other than sevoflurane itself, that has an intact 1,1,1,3,3,3-hexafluoroisopropoxy moiety[(CF3)2CHO—], and contains one or more moieties susceptible to acidic hydrolysis, such that HFIP is released upon such treatment. The process is useful, among other things, for recovering HFIP from waste streams associated with the synthesis of the inhalation anesthetic, fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether (“sevoflurane”). The process includes heating the composition with a strong protic acid to a temperature effective to hydrolyze at least some of the HFIP hydrolyzable precursor to HFIP, and then isolating the HFIP from the heated composition.Type: ApplicationFiled: January 12, 2004Publication date: July 29, 2004Applicant: Baxter International IncInventors: Leonid A. Rozov, Ralph A. Lessor
-
Patent number: 5886239Abstract: A method of preparing fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether (sevoflurane) and structurally related monofluoromethyl ethers in which the monochloromethyl ether precursor thereof is reacted with a sterically hindered tertiary amine hydrofluoride salt.Type: GrantFiled: November 21, 1997Date of Patent: March 23, 1999Assignee: Baxter International Inc.Inventors: Linas V. Kudzma, Ralph A. Lessor, Leonid A. Rozov, Keith Ramig
-
Patent number: 5416244Abstract: An improved process for the production of isoflurane is disclosed. Isoflurane is formed by the exhaustive chlorination of 2,2,2-trifluoroethyl difluoromethyl ether with chlorine gas. The reaction mixture, preferably without purification or refining, is treated with UV light in the presence of isopropanol to reduce 1,1-dichloro-2,2,2-trifluoroethyl difluoromethyl ether, the other major component thereof, to isoflurane. Isoflurane is thereby obtained in yields of at least 80%.Type: GrantFiled: September 30, 1991Date of Patent: May 16, 1995Assignee: Ohmeda Pharmaceutical Products Division Inc.Inventors: Leonid A. Rozov, Fernando Quiroz, Gerald G. Vernice
-
Patent number: 5283372Abstract: A process for the preparation of highly purified optical isomers of desflurane, i.e. 2-(difluoromethoxy)-1,1,1,2-tetrafluoroethane, is described wherein the highly purified opposite optical isomer of iso-flurane is reacted with bromine trifluoride in the cold, preferably in the presence of a solvent. A preferred solvent is bromine. The highly purified positive isomer of desflurane is advantageous over the negative isomer or the racemate.Type: GrantFiled: April 15, 1993Date of Patent: February 1, 1994Assignee: Anaquest, Inc.Inventors: Leonid A. Rozov, Chialang Huang, Donald F. Halpern, Gerald G. Vernice
-
Patent number: 5205914Abstract: An improved preparation of desflurane, 1,2,2,2-tetrafluoroethyl difluoromethyl ether utilizing hexafluoropropene epoxide as a starting material. Hexafluoropropene epoxide is advantageous in that it is relatively inexpensive and is environmentally acceptable.Type: GrantFiled: August 14, 1992Date of Patent: April 27, 1993Assignee: Anaquest, Inc.Inventors: Leonid A. Rozov, Chialang Huang, Gerald G. Vernice
-
Patent number: 5015777Abstract: A process for the preparation of aromatic beta-diketones by the reaction of an acetophenone and a molar excess of an alphatic ester or an ester of benzoic acid in the presence of sodium alkoxide condensation agent in an aromatic hydrocarbon solvent. Also disclosed is a method of recycling the solvent and excess ester reactant after separation of the aromatic beta-diketone product.Type: GrantFiled: November 2, 1989Date of Patent: May 14, 1991Assignee: Witco CorporationInventors: Daniel R. Chisolm, Richard A. Weiss, Leonid Rozov